Phase 1, single and repeat dose study to assess safety, tolerability, and pharmacokinetics (PK) of GSK3923868 in participants with Chronic Obstructive Pulmonary Disease (COPD)

Trial Identifier: 214075
Sponsor: GlaxoSmithKline
Collaborator:
N/A
Start Date: January 2023
Primary Completion Date: July 2023
Study Completion Date: July 2023
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Germany, Berlin Berlin, Germany, 14050